LEUKEMIA GENETIC PROFILE – ANY 6 MARKERS PCR QUALITATIVE Test
Test Details:
A PCR qualitative test for leukemia genetic profiling may include the following six markers:
- BCR-ABL fusion gene: This marker is commonly found in chronic myeloid leukemia (CML) and is caused by a translocation between chromosomes 9 and 22. It leads to the production of an abnormal protein that promotes uncontrolled cell growth.
- FLT3 gene mutation: This marker is frequently found in acute myeloid leukemia (AML). Mutations in the FLT3 gene can lead to the overactivation of a protein that promotes cell division and survival.
- NPM1 gene mutation: NPM1 mutations are also commonly found in AML. These mutations can lead to the abnormal localization of a protein involved in cell growth and division.
- TP53 gene mutation: TP53 mutations are associated with various types of leukemia, including chronic lymphocytic leukemia (CLL) and AML. TP53 is a tumor suppressor gene, and mutations can lead to the uncontrolled growth of cancer cells.
- TET2 gene mutation: TET2 mutations are frequently found in myelodysplastic syndromes (MDS) and other myeloid malignancies. TET2 is involved in the regulation of gene expression, and mutations can lead to abnormal cell growth and differentiation.
- JAK2 gene mutation: JAK2 mutations are commonly found in myeloproliferative neoplasms (MPNs), such as polycythemia vera and essential thrombocythemia. JAK2 is involved in signaling pathways that regulate blood cell production, and mutations can lead to the overproduction of blood cells.
These markers can be detected using PCR (polymerase chain reaction) techniques to amplify specific DNA sequences and determine the presence or absence of genetic abnormalities associated with leukemia. The qualitative nature of the test means it can provide a “yes” or “no” answer regarding the presence of specific genetic markers.
Test Name: LEUKEMIA GENETIC PROFILE – ANY 6 MARKERS PCR QUALITATIVE Test
Components:
Any 6 of the following markers can be selected:
- AML: BCR-ABL, PML-RARA, AML-ETO, INV16, NPM1, FLT3
- ALL: BCR-ABL, MLL-AF9, MLL-AF4, MLL-ENL,t(12;21),t(1;19)
Price: 1550.0 AED
Sample Condition:
3 mL (2 mL min.) whole blood / Bone Marrow Aspirate in 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Specify the 6 markers selected on Test Request Form. Give brief clinical history.
Report Delivery:
Sample Tue / Fri by 11 am; Report Thu / Mon
Method: Real Time PCR
Test Type: Leukemias
Doctor: Oncologist, Hematologist
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information:
Give brief clinical history.
| Test Name | LEUKEMIA GENETIC PROFILE – ANY 6 MARKERS PCR QUALITATIVE Test |
|---|---|
| Components | Any 6 of the following markers can be selected: AML: BCR-ABL, PML-RARA, AML-ETO, INV16, NPM1, FLT3 ALL: BCR-ABL, MLL-AF9, MLL-AF4, MLL-ENL,t(12;21),t(1;19) |
| Price | 1550.0 AED |
| Sample Condition | 3 mL (2 mL min.) whole blood \/ Bone Marrow Aspirate in 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Specify the 6 markers selected on Test Request Form. Give brief clinical history. |
| Report Delivery | Sample Tue / Fri by 11 am; Report Thu / Mon |
| Method | Real Time PCR |
| Test type | Leukemias |
| Doctor | Oncologist, Hematologist |
| Test Department: | MOLECULAR DIAGNOSTICS |
| Pre Test Information | Give brief clinical history. |
| Test Details | A PCR qualitative test for leukemia genetic profiling may include the following six markers: 1. BCR-ABL fusion gene: This marker is commonly found in chronic myeloid leukemia (CML) and is caused by a translocation between chromosomes 9 and 22. It leads to the production of an abnormal protein that promotes uncontrolled cell growth. 2. FLT3 gene mutation: This marker is frequently found in acute myeloid leukemia (AML). Mutations in the FLT3 gene can lead to the overactivation of a protein that promotes cell division and survival. 3. NPM1 gene mutation: NPM1 mutations are also commonly found in AML. These mutations can lead to the abnormal localization of a protein involved in cell growth and division. 4. TP53 gene mutation: TP53 mutations are associated with various types of leukemia, including chronic lymphocytic leukemia (CLL) and AML. TP53 is a tumor suppressor gene, and mutations can lead to the uncontrolled growth of cancer cells. 5. TET2 gene mutation: TET2 mutations are frequently found in myelodysplastic syndromes (MDS) and other myeloid malignancies. TET2 is involved in the regulation of gene expression, and mutations can lead to abnormal cell growth and differentiation. 6. JAK2 gene mutation: JAK2 mutations are commonly found in myeloproliferative neoplasms (MPNs), such as polycythemia vera and essential thrombocythemia. JAK2 is involved in signaling pathways that regulate blood cell production, and mutations can lead to the overproduction of blood cells. These markers can be detected using PCR (polymerase chain reaction) techniques to amplify specific DNA sequences and determine the presence or absence of genetic abnormalities associated with leukemia. The qualitative nature of the test means it can provide a “yes” or “no” answer regarding the presence of specific genetic markers. |
